Article
Environmental Sciences
Yuming Cao, Sihan Chen, Jing Lu, Ming Zhang, Lei Shi, Juling Qin, Jing Lv, Danyang Li, Ling Ma, Yuanzhen Zhang
Summary: BPA exposure reduces the expression of SRB1, inhibits placental proliferation, and increases DNA damage, leading to FGR. These findings provide insights into the mechanism of BPA-associated developmental toxicity and potential therapeutic targets.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2023)
Article
Chemistry, Analytical
Hao-Xiang Liao, Kazuki Bando, Menglu Li, Katsumasa Fujita
Summary: Cell spheroids provide a complex in vitro cell model similar to in vivo tissues. A multifocal Raman spectrophotometer was developed to enable simultaneous analysis of multiple spheroids, allowing for rapid observation of chemical changes in the spheroids.
ANALYTICAL CHEMISTRY
(2023)
Review
Oncology
Ignacio Campillo-Marcos, Raul Garcia-Gonzalez, Elena Navarro-Carrasco, Pedro A. Lazo
Summary: VRK1 is a nuclear Ser-Thr chromatin kinase that is not mutated in cancer, but is overexpressed in many types of tumors and linked to poor prognosis. It plays crucial roles in regulating cell proliferation and DNA damage response pathways, having both pro-tumorigenic effects and protective anti-tumor roles depending on the cellular context.
Article
Cell Biology
Akram Hamidi, Alexandra Wolf, Rositsa Dueva, Melanie Kaufmann, Kirsten Goepelt, George Iliakis, Eric Metzen
Summary: This study established an in vitro model of murine hepatocyte derived cells and analyzed the role of HIF-1 alpha in apoptosis induction, DNA damage repair, and sensitivity to ionizing radiation. The results showed that HIF-1 alpha deficiency increased radiation sensitivity and affected DNA repair.
Article
Biology
Madeleine Hart, Sophie D. Adams, Viji M. Draviam
Summary: Nuclear atypia is a hallmark of cancer, and its immediate and long-term impact on cells can be determined through single-cell tracking studies. Multinucleation, a form of nuclear atypia, blocks cell proliferation in p53-compromised cells by increasing DNA damage and causing replication stress, suggesting potential therapeutic approaches for limiting tumor heterogeneity.
COMMUNICATIONS BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Wenjun Yu, Haixia Xu, Zhe Sun, Yuxin Du, Shiqun Sun, Miyesaier Abudureyimu, Mengjiao Zhang, Jun Tao, Junbo Ge, Jun Ren, Yingmei Zhang
Summary: This study identified the crucial role of TBC domain family member 15 (TBC1D15) in doxorubicin (DOX)-induced cardiotoxicity. TBC1D15 was found to regulate myocardial function, apoptosis, mitochondrial injury, and DNA damage, possibly through its interaction with DNA-dependent protein kinase catalytic subunit (DNA-PKcs). The findings suggest that TBC1D15 may be a potential therapeutic target for the treatment of DOX-induced cardiotoxicity.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Pharmacology & Pharmacy
Ocean Han, Kyle Bromma, Nicholas Palmerley, Ariadne T. Bido, Mesa Monica, Abdulaziz Alhussan, Perry L. Howard, Alexandre G. Brolo, Wayne Beckham, Abraham S. Alexander, Devika B. Chithrani
Summary: One of the major issues in current radiotherapy is the normal tissue toxicity. This study investigates the use of gold nanoparticles and bleomycin as a combination of radiosensitizers to enhance the effect of radiotherapy. The results show that the combination significantly reduces cell growth and is effective in causing DNA double-strand breaks. The incorporation of nanomedicine with radiotherapy has promising clinical applications.
Article
Multidisciplinary Sciences
Yasutoshi Nozaki, Hayato Hikita, Satoshi Tanaka, Kenji Fukumoto, Makiko Urabe, Katsuhiko Sato, Yuta Myojin, Akira Doi, Kazuhiro Murai, Sadatsugu Sakane, Yoshinobu Saito, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara
Summary: This study found that enhanced tumor formation from DEN-transformed hepatocytes by persistent hepatocyte apoptosis is mediated by increased oxidative stress, independent of compensatory liver regeneration. Controlling oxidative stress may play a critical role in suppressing hepatocarcinogenesis for patients with livers harboring transformed cells.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Rachel A. Caston, Paola Fortini, Kevin Chen, Jack Bauer, Eugenia Dogliotti, Y. Whitney Yin, Bruce Demple
Summary: After cellular differentiation, the expression of Fen1 and DNA2, which are involved in repairing mitochondrial DNA, decreases, while MGME1 and ExoG show minimal changes. Neuronal cells maintain mitochondrial DNA repair upon differentiation, relying on mitochondria-specific enzymes for BER.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Qing Tao, Hongjie Ji, Yongjie Zhou, Yuke Shu, Yuwei Chen, Mingyang Shao, Zhenru Wu, Menglin Chen, Tao Lv, Yujun Shi
Summary: By controlling DNA damage repair and gene transcription, HDAC3 plays important roles in liver cancer, liver regeneration, and liver homeostasis. HDAC3 deficiency leads to defective liver morphology and metabolism, and an accumulation of DNA damage in hepatocytes along the portal-central axis. Interestingly, HDAC3 ablation does not impair liver homeostasis until the accumulation of DNA damage occurs. Moreover, HDAC3 deficiency affects the response to DNA damage and enhances radiotherapy sensitivity in hepatocellular carcinoma cells. These findings suggest that selective HDAC3 inhibition may improve the effectiveness of chemoradiotherapy in cancer treatment.
LABORATORY INVESTIGATION
(2023)
Article
Cell Biology
Yong Wang, Fen Liu, Chen Fang, Liyao Xu, Lin Chen, Zeyao Xu, Jiaquan Chen, Wei Peng, Biqi Fu, Yong Li
Summary: The combination treatment of RAPA and SAHA significantly enhances the inhibitory effect of radiotherapy on NSCLC, primarily by modulating the expression of DNA damage proteins and increasing radiotherapy sensitivity. This combined therapy also effectively inhibits tumor growth in the A549 xenograft model.
Article
Gastroenterology & Hepatology
Verena von Buelow, Sarah Gindner, Anne Baier, Laura Hehr, Nicola Buss, Lena Russ, Sarah Wrobel, Victoria Wirth, Kuscha Tabatabai, Thomas Quack, Simone Haeberlein, Patrik Kadesch, Stefanie Gerbig, Katja R. Wiedemann, Bernhard Spengler, Annabel Mehl, Gertrud Morlock, Gabriele Schramm, Joern Pons-Kuehnemann, Franco H. Falcone, R. Alan Wilson, Katrin Bankov, Peter Wild, Christoph G. Grevelding, Elke Roeb, Martin Roderfeld
Summary: In this study, it was demonstrated that soluble egg products of the parasite S. mansoni completely reprogram lipid and carbohydrate metabolism, causing oxidative stress-induced cell damage in the host parenchyma. The eggs take advantage of the host environment through metabolic reprogramming of hepatocytes and enterocytes, and induce DNA damage, promoting hepatocellular damage. These findings have important implications for international health efforts.
Article
Cell Biology
Jiyeon Leem, Guang-Yu Bai, Jeong Su Oh
Summary: Maintaining genome integrity in germ cells is crucial for successful fertilization and embryo development. This study showed that inhibiting WIP1 activity enhances zygotic repair of paternal DNA damage, improving the development and genome activation in zygotes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Cell Biology
Maria B. Birkisdottir, Dick Jaarsma, Renata M. C. Brandt, Sander Barnhoorn, Nicole van Vliet, Sandra Imholz, Conny T. van Oostrom, Bhawani Nagarajah, Eliana Portilla Fernandez, Anton J. M. Roks, Ype Elgersma, Harry van Steeg, Jose A. Ferreira, Jeroen L. A. Pennings, Jan H. J. Hoeijmakers, Wilbert P. Vermeij, Martijn E. T. Dolle
Summary: Experimental results show that although dietary restriction and rapamycin can extend the lifespan of some organisms, rapamycin cannot increase the lifespan and healthspan of progeroid DNA repair-deficient mice like dietary restriction does.
Article
Biochemistry & Molecular Biology
Indrajeet Ghodke, Michaela Remisova, Audrey Furst, Sinan Kilic, Bernardo Reina-San-Martin, Anna R. Poetsch, Matthias Altmeyer, Evi Soutoglou
Summary: AHNAK functions as a modulator of 53BP1 by controlling its multimerization potential, thereby affecting the activity of the p53 signaling pathway, resulting in different cell responses in cancer cells and non-transformed cells. Loss of AHNAK sensitizes cells to combinatorial cancer treatments by suppressing p53 target gene networks in tumors.
Editorial Material
Gastroenterology & Hepatology
Arndt Vogel, Anna Saborowski
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Laura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, Stefan Buettner, Kirsten Utpatel, Heinz-Josef Klumpen, Jorge Adeva, Arndt Vogel, Ana Lleo, Luca Fabris, Mariano Ponz-Sarvise, Raffaele Brustia, Vincenzo Cardinale, Chiara Braconi, Gianpaolo Vidili, Nigel B. Jamieson, Rocio Ir Macias, Jan Philipp Jonas, Marco Marzioni, Waclaw Holowko, Trine Folseraas, Juozas Kupcinskas, Zeno Sparchez, Marcin Krawczyk, Lukasz Krupa, Viorel Scripcariu, Gian Luca Grazi, Ana Landa-Magdalena, Jan Nm Ijzermans, Katja Evert, Joris Erdmann, Flora Lopez-Lopez, Anna Saborowski, Alexander Scheiter, Alvaro Santos-Laso, Guido Carpino, Jesper B. Andersen, Jose Jg Marin, Domenico Alvaro, Luis Bujanda, Alejandro Forner, Juan W. Valle, Bas Groot Koerkamp, Jesus M. Banales
Summary: This study investigates the clinical course of cholangiocarcinoma in a pan-European cohort and finds that the disease is frequently diagnosed at an advanced stage and a proportion of patients fail to receive cancer-specific therapies, resulting in a poor prognosis.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Arndt Vogel, Martina Sterneck, Florian Vondran, Oliver Waidmann, Ingo Klein, Udo Lindig, Silvio Nadalin, Utz Settmacher, Frank Tacke, Hans Juergen Schlitt, Henning Wege
Summary: Multiple systemic therapy options have been approved for HCC treatment, with immuno-oncology combination therapies showing impressive response rates. However, using immunotherapeutics in the context of liver transplantation may increase the risk of rejection.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2022)
Article
Oncology
Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Musharraf Navaid, Abdul Rafeh Naqash, Anuhya Gampa, Umut Ozbek, Junk-Yi Lin, Ylenia Perone, Bruno Vincenzi, Marianna Silletta, Anjana Pillai, Yinghong Wang, Uqba Khan, Yi-Hsiang Huang, Dominik Bettinger, Yehia I. Abugabal, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Luca Di Tommaso, Masatoshi Kudo, Arndt Vogel, Francesco A. Mauri, Alessio Cortellini, Rohini Sharma, Antonio D'Alessio, Celina Ang, David J. Pinato
Summary: The study found that blood inflammatory markers can predict the survival and response of patients with advanced hepatocellular carcinoma treated with immunotherapy. Neutrophile to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were identified as independent prognostic factors.
Article
Oncology
Cornelia L. A. Dewald, Mia-Maria Warnke, Roland Bruening, Martin A. Schneider, Peter Wohlmuth, Jan B. Hinrichs, Anna Saborowski, Arndt Vogel, Frank K. Wacker
Summary: Percutaneous hepatic perfusion (PHP) with melphalan delivers high-dose chemotherapy to hepatic tumors while minimizing systemic toxicity. This study examined the safety, response to therapy, and survival of patients with liver-dominant metastatic uveal melanoma (UM) treated with PHP. The study analyzed a total of 66 patients with liver-dominant metastasized uveal melanoma treated with 145 PHP, and found an overall response rate (ORR) of 59% and disease control rate (DCR) of 93.4%. The median hepatic progression-free survival (PFS) was 12.4 months and median overall survival (OS) was 18.4 months. Adverse events (AEs) included hematologic toxicity and hepatic toxicity, as well as cardiovascular events. In conclusion, PHP is a safe and effective salvage treatment for liver-dominant metastatic uveal melanoma, but careful patient selection is required due to rare serious AEs.
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel
Summary: This study retrospectively analyzed the genomic data of 6,130 patients diagnosed with intrahepatic cholangiocarcinoma (iCCA), and identified seven oncogenic driver genes and their co-mutational patterns. The study also discovered genetic variations and genomic patterns associated with iCCA, which are important for developing effective treatment strategies and predicting mechanisms of resistance.
JOURNAL OF HEPATOLOGY
(2023)
Review
Oncology
Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.
Article
Oncology
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Jaekyung Cheon, Naoshi Nishida, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Yi-Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schoenlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Rohini Sharma, Alessio Cortellini, Vincent E. Gaillard, Hong Jae Chon, David J. Pinato, Celina Ang
Summary: Immunotherapy is the standard front-line therapy for advanced hepatocellular carcinoma, but many patients do not respond to it. This study evaluated the prognostic value of blood-based markers of inflammation and found that they may predict survival outcomes in patients treated with immunotherapy.
Letter
Gastroenterology & Hepatology
Tim Meyer, Sevasti Galani, Andre Lopes, Arndt Vogel
JOURNAL OF HEPATOLOGY
(2023)
Article
Cell Biology
Tom Pieper, Kristian Daniel Ralph Roth, Viktor Glaser, Tobias Riet, Laura Elisa Buitrago-Molina, Maike Hagedorn, Maren Lieber, Michael Hust, Fatih Noyan, Elmar Jaeckel, Matthias Hardtke-Wolenski
Summary: Adoptive transfer of antigen-specific regulatory T cells (Tregs) has shown promising results in treating autoimmune diseases. However, obtaining sufficient antigen-specific Tregs from patients with autoimmune disorders remains challenging. In this study, researchers aimed to generate CARs against TSPAN7, a membrane protein highly expressed on the surface of pancreatic beta cells, using phage display technology. Although the resulting CARs were functional and specifically activated by the target structure, they could not recognize TSPAN7 on the surface of beta cells. This study demonstrates the power of CAR technology in generating antigen-specific T cells and provides new approaches for functional CAR generation.
Article
Cell Biology
Valerie Saetzler, Tobias Riet, Andrea Schienke, Pierre Henschel, Kiara Freitag, Alexander Haake, Frank L. Heppner, Laura Elisa Buitrago-Molina, Fatih Noyan, Elmar Jaeckel, Matthias Hardtke-Wolenski
Summary: In this study, a chimeric antigen receptor (CAR) targeting beta-amyloid was generated using an antibody-like single-chain variable fragment from a phage library. The obtained CAR-Tregs showed antigen-specific activation and suppressive capacity. This study highlights the potential of CAR technology in generating antigen-specific Tregs and provides novel approaches for developing functional CARs.
Article
Oncology
Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Joern Ruessel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Goehler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Carsten Bokemeyer, Joerg Steighardt, Franziska Cygon, Stefan Ibach, Alexander Stein, Joseph Tintelnot
Summary: The study confirms the effectiveness and tolerability of FOLFOXIRI plus bevacizumab as a first-line treatment for mCRC, but challenges remain in its clinical implementation.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Janine Dywicki, Laura Elisa Buitrago-Molin, Fatih Noyan, Ana C. Davalos-Misslitz, Katharina L. Hupa-Breier, Maren Lieber, Martin Hapke, Jerome Schlue, Christine S. Falk, Solaiman Raha, Immo Prinz, Christian Koenecke, Michael P. Manns, Heiner Wedemeyer, Matthias Hardtke-Wolenski, Elmar Jaeckel
Summary: Studies have shown that feeding NASH-resistant BALB/c mice with a high-fat high-carbohydrate diet can activate intrahepatic T cells, while the absence of the adaptive immune response has a significant impact on NASH. The increase in intrahepatic Treg numbers in NASH patients did not improve NASH and unexpected had negative effects when Treg transfer or anti-CD3 therapy were attempted.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Oncology
Sabrina Welland, Tiago deCastro, Melanie Bathon, Thomas Christian Wirth, Tanja Reineke-Plaass, Michael Saborowski, Ulrich Lehmann, Anna Saborowski, Arndt Vogel
Summary: This study aimed to evaluate the regulatory processes associated with off-label precision oncology treatments and found that a significant subset of GI cancer patients were able to benefit from targeted therapies identified through molecular testing. Despite some rejections, a considerable proportion of patients received targeted therapies and demonstrated treatment efficacy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
